Assessment
PD, tumor, death
ADVERSE EVENTS, TUMOR, ADVERSE EVENT
Clinical examination and laboratory evaluation were required before each treatment cycle. After baseline assessment, tumor status was assessed using computed tomography scanning and tumor markers every 6 weeks until achieving PD according to the RECIST guideline version 1.1 (Safety was evaluated based on adverse event (AE) reports, laboratory test results, and vital sign measurements. AE evaluation was classified according to the common terminology criteria for adverse events (CTCAE) version 4.0, where level 1 indicates a mild AE, level 2 indicates a moderate AE, level 3 indicates a serious AE or one that is medically significant but not immediately life-threatening, level 4 indicates a life-threatening AE, and level 5 indicates death.